Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0038389992
Fri, 17.02.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]
Fri, 17.02.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
February 17, 2023
Annual report of BB Biotech AG as at December 31, 2022
BB Biotech AG publishes its 2022 annual report
BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]
Fri, 20.01.2023
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
January 20, 2023
BB Biotech AG closes the 2022 fiscal year with a loss
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022.
Based on its preliminary unaudited consolidated figures, BB [ … ]
Fri, 20.01.2023
BB BIOTECH AG
Media release as at January 20, 2023
Portfolio of BB Biotech AG as at December 31, 2022
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
The year 2022 saw volatile market conditions for global equity and bond markets, with substantial stepwise increases in central bank rates, led by the US [ … ]
Thu, 08.12.2022
BB BIOTECH AG
Market commentary, December 8, 2022
Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management
Molecular strike force for the immune system
The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.
Autoim [ … ]
Thu, 08.12.2022
BB BIOTECH AG
Market commentary, December 8, 2022
Dr. Daniel Koller, Head of BB Biotech’s Investment Management Team at Bellevue Asset Management
Molecular strike force for the immune system
The increasing number of market-ready new therapies for previously incurable and hard-to-treat autoimmune diseases is creating attractive investment opportunities.
Autoim [ … ]
Fri, 21.10.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss [ … ]
Fri, 21.10.2022
BB BIOTECH AG
Ad hoc announcement pursuant to Art. 53 LR
October 21, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2022, which covers the results of its business activities for the first nine months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss [ … ]
Fri, 21.10.2022
BB BIOTECH AG
Media release as at October 21, 2022
Interim report of BB Biotech AG as at September 30, 2022
US drug pricing legislation drives biotech business to adapt for further innovation
Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid [ … ]
Fri, 21.10.2022
BB BIOTECH AG
Media release as at October 21, 2022
Interim report of BB Biotech AG as at September 30, 2022
US drug pricing legislation drives biotech business to adapt for further innovation
Financial markets remained volatile throughout the third quarter, and the healthcare sector was no exception. The US Inflation Reduction Act (IRA) signed into law in mid [ … ]